8-K/A: Ocugen Secures $30 Million Loan Facility with Avenue Capital, Issues Equity to Lenders

Ocugen, Inc. enters into a $30 million loan and security agreement with Avenue Capital, issuing shares of common stock and granting conversion rights to the lenders.

Summary

• Ocugen, Inc. has entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. for up to $30 million.
• The loan proceeds will be used for working capital and general corporate purposes.
• The Term Loans mature on November 1, 2028.
• The interest rate is variable, equal to 4.25% plus the prime rate, subject to a prime floor based on The Wall Street Journal prime rate on the closing date.
• The company will pay a final payment of 4.25% of the Loan Amount upon maturity or prepayment.
• Prepayment fees range from 0.5% to 3.0% of the outstanding principal balance, depending on when the prepayment occurs.
• The loan is collateralized by all of the company's assets, and the lenders have a negative pledge on the company's intellectual property.
• The lenders have the right to convert up to $6.0 million of the outstanding principal amount into shares of Common Stock at 80% of the trading price on the date of conversion.
• Ocugen issued 211,268 shares of Common Stock to Avenue 1 and 845,070 shares of Common Stock to Avenue 2 in connection with the loan agreement.
• The company will file a registration statement with the SEC within 90 days to register the resale of these shares and the shares issuable upon conversion.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While securing financing is generally positive, the terms of the loan, including the security interest and conversion rights, introduce potential risks for existing shareholders.

Positives

• The loan provides Ocugen with additional working capital and funding for general corporate purposes.
• The conversion option allows lenders to participate in potential upside if Ocugen's stock price increases.
• The loan terms include an interest-only period, which may provide some short-term financial flexibility.
• The company retains the option to prepay the Term Loans in their entirety.

Negatives

• The loan is secured by all of Ocugen's assets, increasing the risk to the lenders but also increasing the risk to shareholders.
• The variable interest rate exposes Ocugen to potential increases in borrowing costs if prime rates rise.
• The conversion option could dilute existing shareholders if lenders choose to convert their debt into equity.
• Prepayment of the loan incurs a prepayment fee.

Risks

• Failure to comply with the covenants in the Loan and Security Agreement could trigger an event of default.
• A material adverse effect on the company could trigger an event of default.
• The company's ability to repay the loan depends on its future financial performance.
• The negative pledge on intellectual property could limit the company's ability to raise additional capital or monetize its assets.
• The conversion option could dilute existing shareholders if lenders choose to convert their debt into equity.

Future Outlook

The company intends to use the proceeds of the Term Loans for working capital and general corporate purposes.

Industry Context

Venture debt is a common financing tool for development stage biotech companies that may not yet have revenue or positive cash flow. The terms of the loan, including interest rate, warrants, and covenants, are typical for this type of financing.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as BioCryst Pharmaceuticals and Halozyme Therapeutics, have utilized similar debt financing strategies to fund research and development activities.
• The interest rate and fees associated with Ocugen's loan are within the typical range for venture debt in the biotech industry, which often includes a combination of a base rate plus a margin over a benchmark like prime or LIBOR/SOFR.
• The inclusion of warrants or conversion rights is also a common feature in venture debt deals, providing lenders with the potential for equity upside if the company performs well.
• The specific terms of Ocugen's loan, such as the prepayment penalties and financial covenants, are tailored to the company's specific circumstances and risk profile, but generally align with industry standards for venture debt financing.

Stakeholder Impact

• Shareholders may experience dilution if lenders convert their debt into equity.
• Employees benefit from the company's increased financial stability.
• Customers and suppliers can expect continued operations and partnerships.
• Creditors are impacted by the new debt and security interests.

Next Steps

• Ocugen will use the loan proceeds for working capital and general corporate purposes.
• The company will file a registration statement with the SEC within 90 days to register the resale of the shares issued to the lenders and the shares issuable upon conversion.
• Lenders may choose to exercise their conversion rights in the future.

Key Dates